Drug Profile
Research programme: endometriosis therapeutics - InNexus Biotechnology/ St. Joseph's Hospital and Medical Center
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator InNexus Biotechnology; St Josephs Hospital and Medical Center
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Endometriosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Endometriosis in USA (Parenteral)
- 19 Sep 2008 Preclinical trials in Endometriosis in USA (Parenteral)